OUR TECHNOLOGY
Since succinate is elevated in many pathological situations with a metabolic and/or a inflammatory component, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation, being our first clinical indication type 2 diabetes.
We are developing first-in-class, gut- restricted, monitorable, succinate-modulating therapies as a new opportunity for patients with metabolic and inflammatory diseases.
SUCCINATE AT A GLANCE
WHY SUCCINATE?
We have demonstrated that intestinal succinate is a relevant source of circulating succinate, thus setting the stage for the development of our propietary gut-restricted succinate-decreasing therapies to treat inflammatory and metabolic diseases, being type 2 diabetes our first clinical indication.